Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 15/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 15/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.45 |
| ▸ | BCL2 | P10415 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 2/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | IL1B | P01584 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30738793 | 1.00 | DDB1 (0.49) | DDB1CRBNBRD4IKZF3ALDH1A1 | |
| SCHEMBL30273524 | 0.97 | CRBN (0.46) | DDB1CRBNBRD4IKZF3ALDH1A1 | |
| SCHEMBL30273812 | 0.95 | CRBN (0.46) | DDB1CRBNBRD4IKZF3ALDH1A1 | |
| SCHEMBL25036577 | 0.91 | CRBN (0.45) | DDB1CRBNBRD4IKZF3ALDH1A1 | |
| SCHEMBL29584536 | 0.90 | DDB1 (0.47) | DDB1CRBNBRD4IKZF3ALDH1A1 | |
| SCHEMBL22533289 | 0.90 | DDB1 (0.47) | DDB1CRBNBRD4IKZF3ALDH1A1 | |
| SCHEMBL24329637 | 0.88 | BRD4 (0.50) | DDB1CRBNBRD4BCL2L11BCL2 | |
| SCHEMBL29583780 | 0.88 | BRD4 (0.50) | DDB1CRBNBRD4BCL2L11BCL2 | |
| SCHEMBL22532800 | 0.88 | CRBN (0.54) | DDB1CRBNBRD4IKZF3 | |
| SCHEMBL30274063 | 0.88 | DDB1 (0.47) | DDB1CRBNBRD4IKZF3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101540-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | ABBVIE BIOTECHNOLOGY LTD (BM) | 2024-03-28 | — | — | US | disclosed |
| US-20240051946-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | ABBVIE BIOTECHNOLOGY LTD (BM) | 2024-02-15 | — | — | US | disclosed |
| WO-2024026081-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | RIBON THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026083-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | RIBON THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026083-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | RIBON THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051946-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | PARP14, PARP15, PARP16 | DDB1 54/4885CRBN 422/4885BRD4 13/4885 |
| US-20240101540-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | PARP14, PARP15, PARP16 | DDB1 54/4885CRBN 422/4885BRD4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.